CCL5/RANTES Antibody [Biotin]

• Reactivity: Mu
• Applications: WB, ELISA(Det)
• Clonality: Polyclonal
• Host: Goat
• Conjugate: Biotin
• Concentration: LYOPH

CCL5/RANTES Antibody [Biotin] Summary

• Immunogen: E. coli-derived recombinant mouse CCL5/RANTES
• Specificity: Detects mouse CCL5/RANTES in ELISAs and Western blots. In sandwich immunoassays, approximately 1% cross-reactivity with recombinant human (rh) CCL5 is observed and less than 0.1% cross-reactivity with recombinant mouse VIC, rhVIC, and rhTECK is observed.
• Source: N/A
• Isotype: IgG
• Clonality: Polyclonal
• Host: Goat
• Gene: CCL5
• Purity Statement: Antigen Affinity-purified

Applications/Dilutions

• Dilutions:
  • ELISA Capture (Matched Antibody Pair) 2-8 ug/mL
  • ELISA Detection (Matched Antibody Pair) 0.1-0.4 ug/mL
  • ELISA Standard (Matched Pair)
  • Western Blot 0.1 ug/mL
• Application Notes: ELISA Capture: Mouse CCL5/RANTES Antibody (Catalog # MAB4781)
  ELISA Detection: Mouse CCL5/RANTES Biotinylated Antibody (Catalog # BAF478)
  Standard: Recombinant Mouse CCL5/RANTES (Catalog # 478-MR)
• Readout System:
  • Streptavidin Native Protein NBP2-29367
  • Streptavidin Native Protein NBP2-29370
  • Streptavidin Native Protein NBP2-29371

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with BSA as a carrier protein.
• Preservative: No Preservative
• Concentration: LYOPH
• Reconstitution Instructions: Reconstitute at 0.2 mg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for CCL5/RANTES Antibody [Biotin]

• CCL5
• chemokine (C-C motif) ligand 5
• D17S136Enormally T-expressed, and presumably secreted
• EoCP
• Eosinophil chemotactic cytokine
• RANTES
• SISd
• SIS-delta
• small inducible cytokine A5 (RANTES)
• small inducible cytokine subfamily A (Cys-Cys), member 5
• Small-inducible cytokine A5
• T cell-specific protein P228
• T-cell specific protein p288
• TCP228T-cell-specific protein RANTES

Background

CCL5, also known as RANTES (Regulated upon Activation, Normal T cell Expressed and presumably Secreted), is an 8 kDa beta -chemokine that plays a primary role in the inflammatory immune response by means of its ability to attract and activate leukocytes (1 - 3). Human and mouse RANTES exhibit cross-species activity on human and mouse cells (4). Mature mouse CCL5 shares 100% aa sequence identity with rat CCL5 and 75% - 88% with canine, cotton rat, feline, and human CCL5 (5). CCL5 is secreted by many cell types at inflammatory sites, and it exerts a wide range of activities through the receptors CCR1, CCR3, CCR4, and CCR5 (6, 7). Inflammatory responses can be impaired by the sequestration of CCL5 by the cytomegalovirus protein US28 (8). In humans, CCR5 binding to CCL5 inhibits the infectivity of R5 (M-tropic) but not X4 (T-tropic) strains of HIV-1 (9). The two N-terminal residues of CCL5 can be removed by CD26/DPPIV, generating a protein that functions as a chemotaxis inhibitor and more effectively blocks M-tropic HIV-1 infection of monocytes (10). Oligomerization of CCL5 on glycosaminoglycans is required for CCR1-mediated leukocyte adhesion and activation as well as CCL5’s interaction with the chemokine CXCL4/PF4 (11 - 13). The deposition of CCL5 on activated vascular endothelial cells is crucial for monocyte adhesion to damaged vasculature, but CCL5 oligomerization is not required for the extravasation of adherent leukocytes (14 - 16). CCL5 is upregulated in breast cancer and promotes tumor progression through the attraction of proinflammatory macrophages in addition to its actions on tumor cells, stromal cells, and the vasculature (17).

1. Schall, T.J. et al. (1990) Nature 347:669.
2. Bacon, K.B. et al. (1995) Science 269:1727.
3. Fischer, F.R. et al. (2001) J. Immunol. 167:1637.
4. Schall, T.J. et al. (1992) Eur. J. Immunol. 22:1477.
5. Heeger, P. et al. (1992) Kidney Int. 41:220.
6. Appay, V. and S.L. Rowland-Jones (2001) Trends Immunol. 22:83.
7. Levy, J.A. (2009) J. Immunol. 182:3945.
8. Randolph-Habecker, J.R. et al. (2002) Cytokine 19:37.
9. DeVico, A.L. and R.C. Gallo (2004) Nat. Rev. Microbiol. 2:401.
10. Proost, P. et al. (1998) J. Biol. Chem. 273:7222.
11. Appay, V. et al. (1999) J. Biol. Chem. 274:27505.
12. Proudfoot, A.E.I. et al. (2003) Proc. Natl. Acad. Sci. USA 100:1885.
13. von Hundelshausen, P. et al. (2005) Blood 105:924.
14. von Hundelshausen, P. et al. (2001) Circulation 103:1772.
15. Zernecke, A. et al. (2008) Arterioscler. Thromb. Vasc. Biol. 28:1897.
16. Baltus, T. et al. (2003) Blood 102:1985.
17. Soria, G. and A. Ben-Baruch (2008) Cancer Lett. 267:271.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for CCL5/RANTES Antibody (BAF478)(10)

Publications using BAF478

• S Guerrero, E Sánchez-Ti, L Agüí, A González-C, P Yáñez-Sede, JM Pingarrón Development of an Electrochemical CCL5 Chemokine Immunoplatform for Rapid Diagnosis of Multiple Sclerosis Biosensors, 2022-08-07;12(8):. 8/7/2022 [PMID: 36005006]
• Z Pang, R Raudonis, C McCormick, Z Cheng Early growth response 1 deficiency protects host against Pseudomonas aeruginosa lung infection Infect. Immun., 2019-12-17;0(0):. 2019-12-17 [PMID: 31611276] (ELISA Detection, Mouse)
• M Muccioli, H Nandigam, T Loftus, M Singh, A Venkatesh, J Wright, M Pate, K McCall, F Benencia Modulation of double-stranded RNA pattern recognition receptor signaling in ovarian cancer cells promotes inflammatory queues Oncotarget, 2018-11-30;9(94):36666-36683. 2018-11-30 [PMID: 30613350] (ELISA Development (Detection), Human, Mouse)
• AK Verma, TS Waghmare, GR Jachak, SC Philkhana, DS Reddy, A Basu Nitrosporeusine analogue ameliorates Chandipura virus induced inflammatory response in CNS via NF?b inactivation in microglia PLoS Negl Trop Dis, 2018-07-12;12(7):e0006648. 2018-07-12 [PMID: 30001342] (ELISA Development (Detection), Mouse)
• A Venkatesh, H Nandigam, M Muccioli, M Singh, T Loftus, D Lewis, M Pate, F Benencia Regulation of inflammatory factors by double-stranded RNA receptors in breast cancer cells Immunobiology, 2017-11-22;0(0):. 2017-11-22 [PMID: 29331323] (ELISA Development (Detection), Mouse)
• Cancer cell CCL5 mediates bone marrow independent angiogenesis in breast cancer Oncotarget, 2016-12-20;0(0):. 2016-12-20 [PMID: 27863423] (ELISA Development (Detection), Mouse)
• Yang L, Brooks C, Xiao S, Sabbisetti V, Yeung M, Hsiao L, Ichimura T, Kuchroo V, Bonventre J KIM-1-mediated phagocytosis reduces acute injury to the kidney. J Clin Invest, 2015-03-09;125(4):1620-36. 2015-03-09 [PMID: 25751064] (ELISA Development (Detection), Mouse)
• Meng Y, Efimova EV, Hamzeh KW Radiation-inducible immunotherapy for cancer: senescent tumor cells as a cancer vaccine. Mol. Ther., 2012-02-14;20(5):1046-55. 2012-02-14 [PMID: 22334019] (IHC-P, Mouse)
• Kim J, Natarajan S, Vaickus LJ, Bouchard JC, Beal D, Cruikshank WW, Remick DG Diesel exhaust particulates exacerbate asthma-like inflammation by increasing CXC chemokines. Am. J. Pathol., 2011-10-01;179(6):2730-9. 2011-10-01 [PMID: 21967814] (ELISA Development, Mouse)
• Mosmann T Synthesis of several chemokines but few cytokines by primed uncommitted precursor CD4 T cells suggests that these cells recruit other immune cells without exerting direct effector functions. Eur. J. Immunol., 2004-06-01;34(6):1617-26. 2004-06-01 [PMID: 15162431] (ELISA Development, Mouse)

Bioinformatics

• Gene Symbol: CCL5